Adding flexibility to CRISPR targets in the genome
HIRI researchers find natural ways to overcome limitations of genome-editing tool
CRISPR technologies are revolutionary genome-editing tools that rely on molecular scissors called Cas nucleases to cut DNA. While these scissors can be programmed to cut virtually any sequence, that target must be flanked by a special sequence called a PAM (Protospacer Adjacent Motif). The PAM sequence is up to six nucleotides in length and can vary widely between Cas nucleases. To allow all sites of the genome to be targeted with CRISPR technologies, there is an ongoing push to collect nucleases that cover all possible PAMs. In a current study published in Nucleic Acids Research, researchers from the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg characterized technologically important Cas nucleases to determine how to expand the spectrum of target sequences. The HIRI is a joint institution of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Julius Maximilian University of Würzburg.
“The presence of a suitable PAM remains a barrier for directed gene editing,” says Prof Chase Beisel, head of the HIRI research group “RNA Synthetic Biology”. This has led researchers to mine the existing diversity of Cas nucleases in bacteria and archaea for ones that recognize new and unique PAMs. In his current study, Beisel collaborated with researchers from North Carolina State University and the biotech company Benson Hill to characterize the PAMs recognized by a set of technologically important Cas nucleases called Cas12a. They found that two of the characterized nucleases recognized quite distinct PAMs despite the nucleases being almost identical. Furthermore, when the researchers started mutating one nuclease to look like the other, they uncovered a variant that recognized different PAMs. This nuclease also exhibited more efficient genome editing than either of the original nucleases.
These technologies are also becoming cheap and rapid diagnostics, including for the detection of SARS-CoV-2.
When looking for new and interesting Cas nucleases, researchers would normally evaluate nucleases that are extremely different from each other, with the assumption that similar nucleases behave similarly. “Our work challenges this notion with the surprising finding that similar nucleases can in fact behave quite differently,” says Beisel. Building on this finding, the researchers argue for a deeper mining of nucleases in nature and for mutating existing nucleases to change the PAM. The nuclease mutant with enhanced activity and a unique PAM that was discovered in this study would also be beneficial for CRISPR technologies by allowing Cas12a nucleases to access even more potential DNA targets.
CRISPR technologies are actively applied for gene therapy to combat genetic diseases and for immunotherapy to combat cancer. “These technologies are also becoming cheap and rapid diagnostics, including for the detection of SARS-CoV-2. Our work helps expand the number of potential target sites and thus the flexibility in how these technologies can be applied,” says Beisel. His research group will continue to explore the natural diversity of CRISPR nucleases and CRISPR-Cas immune systems in hopes of revealing new and interesting functions that could bring about the next revolution in CRISPR technologies.
Thomas Jacobsen, Fani Ttofali, Chunyu Liao, Srinivas Manchalu, Benjamin N Gray, Chase L Beisel: Characterization of Cas12a nucleases reveals diverse PAM profiles between closely-related orthologs. Nucleic Acids Research. 2020; DOI: 10.1093/nar/gkaa272